Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Biotech Researchers Invited to Use an Automated, High-Capacity Target Capture-Sequencing Service

By BiotechDaily International staff writers
Posted on 13 Jan 2012
Researchers in need of DNA sequencing data can avail themselves of a new service that provides completely automated, high capacity, target capture-sequencing data, and streamlines sample preparation for targeted next-generation sequencing.

The new service, called targeted resequencing, is an innovation of Beckman Coulter Genomics (Danvers, MA, USA), a leading provider of genomic services and nucleic acid purification products.

Functionally, the service relies on the combination of “Agilent SureSelect Target Enrichment” technology with Beckman Coulter’s “SPRIworks Fragment Library System” for automated library construction and “Biomek Laboratory Automation Workstation” for liquid handling. This platform provides high quality, reproducible samples ready for sequencing. Beckman Coulter Genomics automated target capture solution allows for whole exome capture or custom targeting of genomic regions of interest. Sequencing on the Illumina GAII or HiSeq 2000 instruments provides accurate data with reduced project turnaround time resulting from workflow automation and flexible sample multiplexing options.

“By automating this pipeline and maximizing our target capture sequencing capacity, we are able to offer our customers a high-throughput solution, with faster project turnaround times and reproducible sequencing data,” said Dr. William Donahue, manager of molecular biology for Beckman Coulter Genomics. “Our LIMS [laboratory information management system] sample tracking also enables large numbers of samples to be processed at the same time, significantly reducing the risk of sample mix-up that exists in a manual process.”

Results are delivered via a secure FTP site or are shipped on a portable hard drive depending upon the size of the dataset.

Related Links:

Beckman Coulter Genomics


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.